Complete Story


SYNRIBO (omacetaxine mepesuccinate)

Now Approved for CML

Teva Oncology announced the FDA approval of SYNRIBO for Injection
for the treatment of adult patients with chronic or accelerated phase chronic
myeloid leukemia (CML) with resistance and/or intolerance to two or more
tyrosine kinase inhibitors (TKIs) READ MORE

< Back | Printer Friendly Page